Currently browsing tag


Celldex discontinues late-stage study of brain cancer vaccine

Celldex Therapeutics Inc said it would discontinue a late-stage study of its brain cancer vaccine after an independent interim analysis suggested the therapy might not show a statistically significant benefit in patient survival compared with standard chemotherapy. Celldex shares more than halved to $3.76 in premarket trading on Monday. The vaccine, Rintega, belongs to an emerging class of drugs that spur the immune system to recognize and attack cancer.